Median time to minimal symptoms was 303 minutes ( 240-720 ) in rhC1INH-treated patients vs 483 minutes ( 300-1 ,440 ) in placebo-treated patients based on the TEQ ( P = .078 ) and 240 minutes ( 177-270 ) vs 362 minutes ( 240 , not estimable ; P = .005 ) , based on an overall VAS less than 20 mm .